# Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis

> **NCT03828123** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bioinova, s.r.o.** · enrollment: 26 (actual)

## Conditions studied

- Motor Neuron Disease, Amyotrophic Lateral Sclerosis

## Interventions

- **BIOLOGICAL:** Suspension of human autologous MSC 3P in 1.5 ml

## Key facts

- **NCT ID:** NCT03828123
- **Lead sponsor:** Bioinova, s.r.o.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2017-08-18
- **Final completion:** 2017-08-18
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2019-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03828123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03828123, "Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03828123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*